Eric S Engelman1, Roberto Leon-Ferre, Boris G Naraev, Nancy Sharma, Shiliang Sun, Thomas M O'Dorisio, James Howe, Anna Button, Gideon Zamba, Thorvardur R Halfdanarson. 1. From the *Division of Hematology, Oncology, and Bone and Marrow Transplantation, the Holden Comprehensive Cancer Center, and †Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA; ‡New Mexico Cancer Center, Albuquerque, NM; §Department of Radiology, and ∥Division of Surgical Oncology, University of Iowa Hospitals and Clinics; ¶College of Public Health, University of Iowa Carver College of Medicine, Iowa City, IA; and #Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ.
Abstract
OBJECTIVE: We compared the clinical outcomes of patients with metastatic neuroendocrine tumors treated with hepatic artery embolization (HAE), chemoembolization (HACE), and selective internal radiation therapy (SIRT) at our institution over the last 10 years. METHODS: The medical records of 42 patients with metastatic neuroendocrine tumors with hepatic metastases treated with HAE, HACE, or SIRT at the University of Iowa from 2001 to 2011 were analyzed. RESULTS: A total of 13 patients had HAE, 17 patients had HACE, and 12 patients had SIRT as their initial procedure. Time to progression (TTP) was similar between SIRT (15.1 months) and HACE/HAE groups (19.6 months; P = 0.968). There was a trend toward increased TTP in patients receiving HACE (33.4 months) compared with HAE (12.1 months) or SIRT (15.1 months), although not statistically significant (P = 0.512). The overall survival for all patients from the first intervention was 41.9 months. There was no difference between HACE/HAE and SIRT in posttherapy change of chromogranin A (P = 0.233) and pancreastatin (P = 0.158) levels. Time to progression did not correlate with the change in the posttherapy chromogranin A (P = 0.299) or pancreastatin (P = 0.208) levels. CONCLUSIONS: There was no significant difference in TTP in patients treated with SIRT compared with patients treated with HAE or HACE. Baseline and posttherapy marker changes were not predictive of TTP.
OBJECTIVE: We compared the clinical outcomes of patients with metastatic neuroendocrine tumors treated with hepatic artery embolization (HAE), chemoembolization (HACE), and selective internal radiation therapy (SIRT) at our institution over the last 10 years. METHODS: The medical records of 42 patients with metastatic neuroendocrine tumors with hepatic metastases treated with HAE, HACE, or SIRT at the University of Iowa from 2001 to 2011 were analyzed. RESULTS: A total of 13 patients had HAE, 17 patients had HACE, and 12 patients had SIRT as their initial procedure. Time to progression (TTP) was similar between SIRT (15.1 months) and HACE/HAE groups (19.6 months; P = 0.968). There was a trend toward increased TTP in patients receiving HACE (33.4 months) compared with HAE (12.1 months) or SIRT (15.1 months), although not statistically significant (P = 0.512). The overall survival for all patients from the first intervention was 41.9 months. There was no difference between HACE/HAE and SIRT in posttherapy change of chromogranin A (P = 0.233) and pancreastatin (P = 0.158) levels. Time to progression did not correlate with the change in the posttherapy chromogranin A (P = 0.299) or pancreastatin (P = 0.208) levels. CONCLUSIONS: There was no significant difference in TTP in patients treated with SIRT compared with patients treated with HAE or HACE. Baseline and posttherapy marker changes were not predictive of TTP.
Authors: Khairuddin Memon; Robert J Lewandowski; Mary F Mulcahy; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Vanessa L Gates; Bassel Atassi; Steven Newman; Reed A Omary; Al B Benson; Riad Salem Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-02 Impact factor: 7.038
Authors: Philipp M Paprottka; Ralf-T Hoffmann; Alexander Haug; Wieland H Sommer; Franziska Raessler; Christoph G Trumm; Gerwin P Schmidt; Nima Ashoori; Maximilian F Reiser; Tobias F Jakobs Journal: Cardiovasc Intervent Radiol Date: 2011-08-17 Impact factor: 2.740
Authors: Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Jonathan R Strosberg; Robert L Fine; Junsung Choi; Aejaz Nasir; Domenico Coppola; Dung-Tsa Chen; James Helm; Larry Kvols Journal: Cancer Date: 2010-09-07 Impact factor: 6.860
Authors: Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger Journal: HPB (Oxford) Date: 2010-08 Impact factor: 3.647
Authors: Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold Journal: J Clin Oncol Date: 2009-08-24 Impact factor: 44.544
Authors: Thomas K Rhee; Robert J Lewandowski; David M Liu; Mary F Mulcahy; Gary Takahashi; Paul D Hansen; Al B Benson; Andrew S Kennedy; Reed A Omary; Riad Salem Journal: Ann Surg Date: 2008-06 Impact factor: 12.969
Authors: Andrew S Kennedy; William A Dezarn; Patrick McNeillie; Doug Coldwell; Charles Nutting; Dennis Carter; Ravi Murthy; Steven Rose; Richard R P Warner; David Liu; Holger Palmedo; Carroll Overton; Bonita Jones; Riad Salem Journal: Am J Clin Oncol Date: 2008-06 Impact factor: 2.339
Authors: Julie King; Richard Quinn; Derek M Glenn; Julia Janssen; Denise Tong; Winston Liaw; David L Morris Journal: Cancer Date: 2008-09-01 Impact factor: 6.860
Authors: Lisa Ngo; Ahmed Elnahla; Abdallah S Attia; Mohamed Hussein; Eman A Toraih; Emad Kandil; Mary Killackey Journal: Ann Surg Oncol Date: 2021-01-03 Impact factor: 5.344
Authors: Malgorzata M Bala; Robert P Riemsma; Robert Wolff; Michal Pedziwiatr; Jerzy W Mitus; Dawid Storman; Mateusz J Swierz; Jos Kleijnen Journal: Cochrane Database Syst Rev Date: 2019-07-10
Authors: Boris G Naraev; Magnus Halland; Daniel M Halperin; Amy J Purvis; Thomas M OʼDorisio; Thorvardur R Halfdanarson Journal: Pancreas Date: 2019-09 Impact factor: 3.327
Authors: Thomas Y Wong; Kevin S Zhang; Ripal T Gandhi; Zachary S Collins; Ryan O'Hara; Eric A Wang; Kirubahara Vaheesan; Lea Matsuoka; Daniel Y Sze; Andrew S Kennedy; Daniel B Brown Journal: BMC Cancer Date: 2022-03-01 Impact factor: 4.430
Authors: Jaume Capdevila; Enrique Grande; Rocío García-Carbonero; Marc Simó; Mª Isabel Del Olmo-García; Paula Jiménez-Fonseca; Alberto Carmona-Bayonas; Virginia Pubul Journal: Oncologist Date: 2022-04-05